281 related articles for article (PubMed ID: 36059450)
1. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
Front Immunol; 2022; 13():938269. PubMed ID: 36059450
[TBL] [Abstract][Full Text] [Related]
2. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.
Qi Y; Gu L; Shen J; Yao Y; Zhao Y; Lu S; Chen Z
Front Oncol; 2023; 13():1194100. PubMed ID: 37655106
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
7. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
8. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
Zhang Y; Fu F; Hu H; Wang S; Li Y; Hu H; Chen H
J Thorac Cardiovasc Surg; 2021 Feb; 161(2):434-442.e2. PubMed ID: 32340810
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
11. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
13. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
15. Preoperative endobronchial photodynamic therapy improves resectability in initially irresectable (inoperable) locally advanced non small cell lung cancer.
Akopov A; Rusanov A; Gerasin A; Kazakov N; Urtenova M; Chistyakov I
Photodiagnosis Photodyn Ther; 2014 Sep; 11(3):259-64. PubMed ID: 24704942
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.
Liu Z; Gao Z; Zhang M; Wang X; Gong J; Jiang S; Zhang Z
Ann Thorac Cardiovasc Surg; 2022 Apr; 28(2):111-120. PubMed ID: 34776459
[TBL] [Abstract][Full Text] [Related]
18. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
19. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
[TBL] [Abstract][Full Text] [Related]
20. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
